Identification of genes associated with cervical intervertebral disc degeneration and immune cell infiltration
-
By
-
Dikai Bei
-
Kaifeng Gan
-
Binhui Chen
-
Jie Li
-
June 19, 2026
-
Clinical Scorecard: Discovery of Genetic Markers Linked to Cervical Intervertebral Disc Degeneration and Immune Cell Infiltration
At a Glance
| Category | Detail |
|---|
| Condition | Cervical Intervertebral Disc Degeneration (IDD) |
| Key Mechanisms | Involvement of immune cell infiltration and inflammatory pathways in IDD pathogenesis. |
| Target Population | Patients with cervical intervertebral disc degeneration undergoing anterior cervical discectomy and fusion. |
| Care Setting | Clinical research and diagnostic biomarker identification. |
Key Highlights
- Identification of 71 differentially expressed genes (DEGs) in cervical IDD.
- Key biomarkers CDKN3, SLC22A4, and SYDE1 associated with IDD.
- Significant enrichment in inflammation-related pathways in IDD samples.
- Immune cell infiltration linked to the pathogenesis of cervical IDD.
- Validation of biomarker expression through quantitative PCR.
Guideline-Based Recommendations
Diagnosis
- Utilize identified biomarkers CDKN3, SLC22A4, and SYDE1 for early-stage diagnosis of cervical IDD.
Management
- Monitor disease progression through the expression levels of identified biomarkers.
Monitoring & Follow-up
- Regular assessment of immune cell infiltration and inflammatory cytokine levels in IDD patients.
Risks
- Increased risk of discogenic neck pain associated with cervical intervertebral disc degeneration.
Patient & Prescribing Data
Patients diagnosed with cervical intervertebral disc degeneration.
Further studies are warranted to validate the clinical utility of identified biomarkers.
Clinical Best Practices
- Incorporate genetic biomarker analysis in the diagnostic process for cervical IDD.
- Consider immune cell activity in the management of cervical IDD.
Related Resources & Content
